Physician profile
Muhammad Usama
NPI 1306370077
$72,892.71
in general payments reported to CMS, 2019-2025
8 companies · $72K in 2025
The $72K reported for 2025 was more than what 98% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2024: $88.81 · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Travel and Lodging: $9,176 · Food and Beverage: $2,855 · Education: $11.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,525.00 |
| Travel and Lodging | $9,176.14 |
| Food and Beverage | $2,855.31 |
| Education | $11.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $71,604.41 | 2025 | Zepbound |
| Jazz Pharmaceuticals INC. | $749.60 | 2021-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $149.99 | 2025 | Lumryz |
| Zoll Respicardia, INC. | $147.59 | 2025 | Remede System |
| 3b Medical, INC. | $112.33 | 2025 | Luna |
| Inspire Medical Systems, INC. | $88.81 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $25.65 | 2025 | |
| Axsome Therapeutics, INC. | $14.33 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Usama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.